Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

348 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Tumor antigens recognized by T lymphocytes.
Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Boon T, et al. Annu Rev Immunol. 1994;12:337-65. doi: 10.1146/annurev.iy.12.040194.002005. Annu Rev Immunol. 1994. PMID: 8011285 Review.
Transplantation experiments have demonstrated that most mouse tumors express antigens that can constitute targets for rejection responses mediated by syngeneic T lymphocytes. For human tumors, autologous cultures mixing tumor cells and blood lymphocytes or tumor-infiltrati …
Transplantation experiments have demonstrated that most mouse tumors express antigens that can constitute targets for rejection responses me …
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.
Maryanski JL, Boon T. Maryanski JL, et al. Among authors: boon t. Eur J Immunol. 1982 May;12(5):406-12. doi: 10.1002/eji.1830120509. Eur J Immunol. 1982. PMID: 6178608
Mouse mastocytoma P815 tumor cell variants that express new individual antigens were subjected to immunoselection in vitro with specific cytolytic T lymphocyte (CTL) clones. ...
Mouse mastocytoma P815 tumor cell variants that express new individual antigens were subjected to immunoselection in vitro with specific cyt …
Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.
Carrasco J, Van Pel A, Neyns B, Lethé B, Brasseur F, Renkvist N, van der Bruggen P, van Baren N, Paulus R, Thielemans K, Boon T, Godelaine D. Carrasco J, et al. Among authors: boon t. J Immunol. 2008 Mar 1;180(5):3585-93. doi: 10.4049/jimmunol.180.5.3585. J Immunol. 2008. PMID: 18292586 Clinical Trial.
Anti-MAGE-3.A1 CD8 and anti-MAGE-3.DP4 CD4 T cells became detectable in the blood after vaccination at a frequency of approximately 10(-5) among the CD8 or CD4 T cells, respectively, and they were slightly enriched in slowly progressing metastases. ...The striking s …
Anti-MAGE-3.A1 CD8 and anti-MAGE-3.DP4 CD4 T cells became detectable in the blood after vaccination at a frequency of approximately 1 …
A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma.
Takenoyama M, Baurain JF, Yasuda M, So T, Sugaya M, Hanagiri T, Sugio K, Yasumoto K, Boon T, Coulie PG. Takenoyama M, et al. Among authors: boon t. Int J Cancer. 2006 Apr 15;118(8):1992-7. doi: 10.1002/ijc.21594. Int J Cancer. 2006. PMID: 16287085
We have identified an antigen recognized by cytolytic T lymphocytes (CTL) on the autologous tumor cells of a nonsmall cell lung cancer patient. ...In a lymph node draining the tumor, precursors of CTL recognizing the autologous tumor cells were detected at a frequency of a …
We have identified an antigen recognized by cytolytic T lymphocytes (CTL) on the autologous tumor cells of a nonsmall cell lung cance …
A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells.
Ottaviani S, Zhang Y, Boon T, van der Bruggen P. Ottaviani S, et al. Among authors: boon t. Cancer Immunol Immunother. 2005 Dec;54(12):1214-20. doi: 10.1007/s00262-005-0705-2. Epub 2005 Jul 16. Cancer Immunol Immunother. 2005. PMID: 16025263
Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.
Lurquin C, Lethé B, De Plaen E, Corbière V, Théate I, van Baren N, Coulie PG, Boon T. Lurquin C, et al. Among authors: boon t. J Exp Med. 2005 Jan 17;201(2):249-57. doi: 10.1084/jem.20041378. J Exp Med. 2005. PMID: 15657294 Free PMC article.
The frequency of anti-MAGE-3.A1 T cells was 1.5 x 10(-5) of CD8 T cells in an invaded lymph node, sixfold higher than in the blood. ...Several other antitumor T clonotypes had frequencies >1%. Similar findings were made on a regressing cutaneous metastasis …
The frequency of anti-MAGE-3.A1 T cells was 1.5 x 10(-5) of CD8 T cells in an invaded lymph node, sixfold higher than in the b …
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.
Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Coulie PG, et al. Among authors: boon t. Nat Rev Cancer. 2014 Feb;14(2):135-46. doi: 10.1038/nrc3670. Nat Rev Cancer. 2014. PMID: 24457417 Review.
DNA microarray to monitor the expression of MAGE-A genes.
Zammatteo N, Lockman L, Brasseur F, De Plaen E, Lurquin C, Lobert PE, Hamels S, Boon T, Remacle J. Zammatteo N, et al. Among authors: boon t. Clin Chem. 2002 Jan;48(1):25-34. Clin Chem. 2002. PMID: 11751535
Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.
Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, Boon T. Coulie PG, et al. Among authors: boon t. Immunol Rev. 2002 Oct;188:33-42. doi: 10.1034/j.1600-065x.2002.18804.x. Immunol Rev. 2002. PMID: 12445279 Review.
Blood lymphocytes were stimulated with antigenic peptide followed by detection with tetramer, T-cell cloning, and TCR analysis. In 4/9 regressor patients and in 1/14 progressors we found a low level, usually monoclonal cytolytic T lymphocyte response against the MAG …
Blood lymphocytes were stimulated with antigenic peptide followed by detection with tetramer, T-cell cloning, and TCR analysis. In 4/ …
Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells.
Loriot A, De Plaen E, Boon T, De Smet C. Loriot A, et al. Among authors: boon t. J Biol Chem. 2006 Apr 14;281(15):10118-26. doi: 10.1074/jbc.M510469200. Epub 2006 Feb 22. J Biol Chem. 2006. PMID: 16497664
348 results
Jump to page
Feedback